The Science Of Pylopass | L. Reuteri DSM 17648
Proven results within 56 days.
Natural Solution
Side-effect free. Pylopass is transient, meaning it goes in crowds the 'bad' stomach bacteria and removes it via the stool.
Clinically Proven
L. Reuteri DSM 17648 has been well-research with 4 peer-reviewed RCT's. Pylopass can be used from ages 9+.
Safe Alongside Antibiotics
Pylopass alongside Quadruple therapy improved eradication and showed improvements in symptoms within 28 days.
How Pylopass Works.
The Lactobacillus strain DSM17648 (Pylopass) attaches directly to the stomach bacteria. It 'crowds' around the bacteria and removes it from the stomach and out of the body via your stool.
This is why Pylopass has become a safe, recognised and effective natural alternative for this specific stomach bacteria.
Clinical Trials.
Proven, effective, and natural, Pylopass' efficacy was evaluated in four separate clinical trials, including a randomised, double-blind, and placebo-controlled study.
The research has shown that Pylopass is a safe and natural alternative for this specific stomach bacteria.
The trial results showed that Pylopass independently effectively reduced the bacteria load in 60% of the participants within 56 days. Furthermore, using Pylopass alongside antibiotics reduced the side effects.
62.5% of participants experienced a measurable decrease in bacteria load.
Study 1
Enrolled: 24 stomach bacteria positive participants
Phase 1: 28 days of placebo
Phase 2: 28 days of Pylopass™ (Lactobacillus reuteri DSM17648)
Outcomes:
- 62.5% reduced bacterial load
- Improved gastrointestinal symptoms
- No serious adverse events
Study 2
Enrolled: 14 stomach bacteria positive participants
Phase 1: 14 days of placebo
Phase 2: 14 days of Pylopass™ (Lactobacillus reuteri DSM17648)
Outcomes:
- Significant reduction in negative stomach bacteria.
- No serious adverse events
- Greater effect with even higher bacteria loads
Study 3
Enrolled: 22 stomach bacteria positive participants
Phase 1: 14 days of placebo
Phase 2: 14 days of Pylopass™ (Lactobacillus reuteri DSM17648)
Outcomes:
- Statistically significant reduction in bacterial load
- No adverse effects
- Reduction was still detectable even 24 weeks post-treatment!
Study 4
Enrolled:103 children aged 9-17 years with stomach bacteria associated chronic gastritis.
Treatment arms:
- L. reuteri DSMZ17648 (monotherapy)
- Quadruple therapy + Placebo
- Quadruple therapy + L. reuteri DSM 17648
Treatment durations:
28 days & 56 days.
Outcomes:
- 77.8% eradication with L. reuteri + quadruple therapy
- 60% eradication with L. reuteri monotherapy for 56 days
- Significant reduction in gastric inflammation and atrophy
- Pylopass groups had no diarrhoea unlike the antibiotic groups.
Long-Lasting Results.
Whether you think you might have it or definitely have it, Pylopass is a safe, natural, and side-effect free alternative.
Lactobacillus reuteri offers a unique and new approach to addressing this specific stomach bacteria, which affects 50% of the global population.